Sardh, Eliane http://orcid.org/0000-0002-2366-2213
Balwani, Manisha
Rees, David C.
Anderson, Karl E.
Jia, Gang
Sweetser, Marianne T.
Wang, Bruce
Funding for this research was provided by:
Alnylam Pharmaceuticals
Karolinska Institute
Article History
Received: 25 January 2024
Accepted: 3 July 2024
First Online: 3 October 2024
Declarations
:
: The study protocol and amendments and informed consent form were reviewed and approved by Independent Ethics Committees/Institutional Review Boards prior to commencement of the study. This study was conducted in accordance with Good Clinical Practice as defined by the International Council on Harmonisation, the principles defined in the Declaration of Helsinki and its amendments, and all applicable national and international laws. All patients provided written informed consent.
: Not applicable.
: Eliane Sardh reports receiving grant support and consulting fees, advisory board fees, and lecture fees, paid to Karolinska Institutet, from Alnylam Pharmaceuticals, and is a member of the Ipnet Executive Board.Manisha Balwani reports receiving grant support, advisory board fees from Recordati Rare Diseases; grant support and advisory board fees from Mitsubishi Tanabe; and advisory board fees from Alexion, Genzyme/Sanofi, and Takeda. In addition, Mount Sinai faculty are named Co-Inventors with Alnylam on a patent related to the development of givosiran, the study drug. The Icahn School of Medicine at Mount Sinai receives payments related to this patent from Alnylam, and a portion of these payments are also distributed to faculty and other co-inventors.David C. Rees reports receiving lecture fees from Alnylam Pharmaceuticals.Karl E. Anderson reports receiving grant support and consulting fees from Alnylam Pharmaceuticals, Recordati Rare Diseases, Mitsubishi Tanabe, and Disc Medicine and consulting fees from Moderna Therapeutics.Gang Jia and Marianne T. Sweetser are employed by and own stock and stock options in Alnylam Pharmaceuticals.Bruce Wang reports receiving consulting fees from Alnylam Pharmaceuticals, Recordati Rare Diseases, Mitsubishi Tanabe Pharma, and Disc Medicine; receiving grant support from Alnylam Pharmaceuticals and Mitsubishi Tanabe Pharma; and being a scientific advisor to Alnylam Pharmaceuticals and Recordati Rare Diseases.